Africa NCD Open Lab

H3Africa consortium meeting
Zambia May 2015

SA/CR/0001/15
VISION: Build an integrated and local African healthcare company with the capabilities, people, and portfolio to reach patients in Sub-Saharan Africa.
Africa NCD Open Lab – concept overview

World Class Academic Groups

Scientific Advisory Board

Funding partners

GSK R&D UK Lab

African Research Centres

Access to full range of GSK capabilities

Training Program
Progress to date
External Scientific Advisory Board

Moffat Nyirenda
Malawi

Dwomoa Adu
Ghana

Corey Casper
USA

Tumani Corrah
The Gambia

Julie Makani
Tanzania

Bongani Mayosi
South Africa

Jean Claude Mbanya
Cameroon

Nicola Mulder
South Africa

Nelson Sewankambo
Uganda

Gerald Yonga
Kenya

Heather Zar
South Africa
Call for proposals – kick-starting research efforts

GSK call

- 8 SSA countries in scope
- Up to £4m available together with potential access to GSK expertise
- Call closed Jan 2015
- Proposals now under review
- Aim to start first projects 2H2015

GSK, MRC South Africa, MRC UK call

- Focus is on South Africa
- Up to £5m available (£4m from external partners) together with potential access to GSK expertise
- Proposals must have relevance to wider SSA
- Call closes 28 June 2015
Africa NCD Open Lab – Training, Centres

Scientific Advisory Board

World Class Academic Groups

GSK R&D UK Lab

African Research Centres

Funding partners

Training Program

Access to full range of GSK capabilities
H3Africa - Possible Areas for Collaboration

– Translating H3Africa research findings into potential therapeutics

– Pharmacogenomics (PGx) opportunities:
  – ADME genetic variation
  – ADME activity variation
  – PGx insights in existing H3A projects

– GSK PGx contributions:
  – Design, analysis and interpretation of PGx data
  – Drug metabolism and drug transporter expertise
Thank You